On June 15, 2022, the National Institute for Health and Care Excellence (NICE) announced a new program called Early Value Assessment for Medtech. It will offer a rapid assessment of digital products, devices, and diagnostics for clinical effectiveness and value for money to inform NHS commissioners. Early Value Assessment is being designed to draw in the most promising and impactful medical technologies where the evidence base is still emerging, starting with digital products, in areas where there is the greatest need.
The first two pilot digital health topics (health apps for depression and anxiety) will begin in June 2022 and are expected to be published in October 2022. This is much faster than a full NICE Medtech evaluation meaning benefits will be realized sooner, while companies generate more evidence required for a full NICE evaluation at a later stage. Further topics are expected in mental health, early cancer diagnosis, and cardiovascular disease. Through Early Value Assessment, commissioners will be assured they are choosing products that offer real potential value while further evidence is being developed.
The webinar will be held on July 18, 2022, to provide details of the new program. The registration is available here.
See the full details here.
This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).